Takeda Pharmaceutical (TKPHF) Change in Accured Expenses (2018 - 2026)

Takeda Pharmaceutical's Change in Accured Expenses history runs 9 years deep, the most recent figure standing at $120.1 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 247.0% year-over-year to $120.1 million; the TTM figure through Mar 2026 stood at $85.5 million (down 71.2% YoY), while the FY2026 annual figure was $90.2 million, down 69.58% from the prior year.
• Change in Accured Expenses was $120.1 million for Q1 2026 at Takeda Pharmaceutical, up from -$89.6 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $275.2 million in Q3 2023 to a low of -$1.1 billion in Q4 2023.
• Historically, Change in Accured Expenses has averaged -$9.1 million across 5 years, with a median of $51.9 million in 2022.
• Biggest YoY gain for Change in Accured Expenses was 430.36% in 2023; the steepest drop was 706.83% in 2023.
• A 5-year view of Change in Accured Expenses shows it stood at $173.7 million in 2022, then slumped by 706.83% to -$1.1 billion in 2023, then jumped by 117.07% to $180.0 million in 2024, then sank by 149.81% to -$89.6 million in 2025, then jumped by 234.01% to $120.1 million in 2026.
• The last three Change in Accured Expenses figures came in at $120.1 million (Q1 2026), -$89.6 million (Q4 2025), and $216.7 million (Q3 2025), per Business Quant data.